It has been recognized that the judicious use of antiangiogenic agents such as bevacizumab (BEV), which is a human recombinant vascular endothelial growth factor (VEGF) monoclonal antibody, normalizes tumor vasculature deriving a favorable prognosis in preclinical models and GBM patients 3-6. The gene discussed is VEGFA; the disease is neoplasm.